TBC1D22A

Across TCGA pan-cancer cohorts, TBC1D22A mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TBC1D22A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TBC1D22A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TBC1D22A is over-expressed in tumor.

CCRCC, LSCC, and PDAC are the cancer types where TBC1D22A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TBC1D22A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.233	<.001	11	view →
LSCC	All	All	+0.121	<.001	5	view →
PDAC	All	All	+0.151	.005	4	view →
COAD	All	IV	+0.277	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TBC1D22A–CCRCC

Open the CCRCC breakdown →